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Introduction
Bone resorption by hyperplastic fibrous tissue is a charac-
teristic feature of various disorders, and accumulating evi-
dence suggests that transformed appearing, activated
fibroblast-like cells play a key role in the pathogenesis of
these conditions. One striking example is rheumatoid
arthritis (RA), in which fibroblast-like synoviocytes consti-
tute a considerable proportion of the hyperplastic syn-
ovium and are involved critically in the destruction of
articular cartilage and bone [1]. Aseptic prosthesis loosen-
ing (APL), although apparently different at first sight, is
also among these conditions and is characterized by the
development of a synovial-like interface membrane (SLIM)
between the prosthesis and the adjacent bone. Several
studies have demonstrated similarities between the SLIM
and the hyperplastic synovium in RA [2] and, intriguingly,
there are a number of common features between fibrob-
last-like cells in RA and prosthesis loosening fibroblasts
(PLFs) found at sites of bone resorption in APL. Recent
data indicate that PLFs share some characteristic features
of RA synovial fibroblasts, including anchorage-indepen-
dent proliferation [3,4], escape of contact inhibition [5],
APL = aseptic prosthesis loosening; FACS = fluorescent-activated cell sorter; FCS = foetal calf serum; ICSS = intracranially self-stimulated; PLF =
prosthesis loosening fibroblast; RA = rheumatoid arthritis; SCID = severe combined immunodeficient; SLIM = synovial-like interface membrane;
TNF = tumour necrosis factor.
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Abstract
To date, mesenchymal cells have only been associated with
bone resorption indirectly, and it has been hypothesized that the
degradation of bone is associated exclusively with specific
functions of osteoclasts. Here we show, in aseptic prosthesis
loosening, that aggressive fibroblasts at the bone surface
actively contribute to bone resorption and that this is
independent of osteoclasts. In two separate models (a severe
combined immunodeficient mouse coimplantation model and a
dentin pit formation assay), these cells produce signs of bone
resorption that are similar to those in early osteoclastic
resorption. In an animal model of aseptic prosthesis loosening
(i.e. intracranially self-stimulated rats), it is shown that these
fibroblasts acquire their ability to degrade bone early on in their
differentiation. Upon stimulation, such fibroblasts readily release
acidic components that lower the pH of their pericellular milieu.
Through the use of specific inhibitors, pericellular acidification is
shown to involve the action of vacuolar type ATPases. Although
fibroblasts, as mesenchymal derived cells, are thought to be
incapable of resorbing bone, the present study provides the first
evidence to challenge this widely held belief. It is demonstrated
that fibroblast-like cells, under pathological conditions, may not
only enhance but also actively contribute to bone resorption.
These cells should therefore be considered novel therapeutic
targets in the treatment of bone destructive disorders.
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activation of tumour-associated pathways including proto-
oncogenes [3] and alterations in apoptosis [6]. Apart form
its relevance to orthopaedic surgery, APL is of general
importance to our understanding of molecular mecha-
nisms of fibroblast biology. Unlike the hyperplastic syn-
ovium in RA, which in the course of disease develops from
a thin synovial membrane, the SLIM arises directly from
progenitor cells in the bone marrow. Thus, PLFs probably
originate directly from mesenchymal stem cells in the bone
marrow and thereby render APL an interesting model for
the differentiation of aggressive fibroblast-like cells at a
bone surface.
Although it is well understood that, during the course of
RA and APL, synovium and synovial-like membrane
mediate the progressive destruction of bone, fibroblast-
like cells have been implicated into this process only indi-
rectly. Both RA synovial fibroblasts and PLFs release
relevant matrix-degrading enzymes such as cathepsins,
matrix metalloproteinases and membrane-type matrix
metalloproteinases [7,8], and have been shown to secrete
a number of factors that stimulate osteoclastic bone
resorption [9,10]. In addition, recent data have demon-
strated that fibroblast-like cells mediate the differentiation
of macrophages into osteoclast-like cells [11,12]. The
possibility that fibroblasts as mesenchymal-derived cells
may resorb bone directly, however, has been rejected by
some investigators [13]. Rather, it has been hypothesized
that bone resorption is associated exclusively with specific
functions of osteoclast-like cells that differentiate from the
monocyte/macrophage lineage.
Here we demonstrate, for the first time, that fibroblast-like
cells that develop at the bone surface in APL are capable
of resorbing bone without the help of osteoclasts. In the
severe combined immunodeficient (SCID) mouse coim-
plantation model, isolated human PLFs from late-stage
APL produced signs of bone resorption. When examined
by scanning electron microscopy, human PLFs that were
cultured over extended periods of time on dentin slices
exhibited morphological signs of bone resorption. Using
PLFs from the developing periprosthetic tissue around
knee prostheses of young, intracranially self-stimulated
(ICSS) Wistar rats, we demonstrate that fibroblast-like
cells acquire this ability early in the process of SLIM for-
mation. We suggest that specific conditions, such as
those found at the implant–prosthesis interface of joint
arthroplasties, may induce the differentiation of fibroblast-
like cells that have the potential to resorb bone indepen-
dently of osteoclasts.
Material and method
Isolation of fibroblast-like cells
Tissue samples around loose joint arthroplasties were
obtained from five patients undergoing revision surgery.
Specimens were minced and digested enzymatically
(Dispase I, overnight). Released cells were grown in Dul-
becco’s modified Eagle’s medium (Biochrom KG, Berlin,
Germany) with 10% foetal calf serum (FCS; Gemini Bio-
logical Products, Calabasas, CA, USA) in a humidified 5%
carbon dioxide atmosphere. After allowing the cells to
adhere overnight, nonadherent cells were removed and
the adherent cells were grown further over four passages.
Rat PLFs were obtained from the ICSS Wistar rat model
(see below) accordingly. Following explanation of the rat
prostheses together with the periprosthetic tissue, the
SLIM tissue was removed [14], minced and digested
enzymatically as was done with the human samples.
Again, cells were grown in Dulbecco’s modified Eagle’s
medium with 10% FCS, and there were no differences in
terms of culturing the cells between rat and human PLFs.
Generation of human osteoclasts
Human peripheral blood was drawn from healthy adult
donors. The blood was diluted 1:3 in Hank’s balanced salt
solution (BioxWhittaker Europe, Walkerville, MD, USA),
layered on Biocoll Separation Solution (Biochrom KG)
and centrifuged at 800g for 20 min. Isolated mononuclear
cells were then washed three times in phosphate-buffered
saline and cultured in minimal essential medium-α medium
(GibcoBRL, Eggenstein, Germany) supplemented with
10% heat-inactivated FCS and 2% penicillin/streptomycin
(GibcoBRL). Cells were plated in 24-well plates at
2×10 6 cells/ml in the presence of RANKL (receptor acti-
vator of nuclear factor-κB ligand) at 50ng/ml (Serotec,
Düsseldorf, Germany) and macrophage colony-stimulating
factor at 25ng/ml (R&D Systems, Wiesbaden, Germany)
[15]. The cultures were fed by replacing half of the
medium every 3 days. After 14 days, osteoclasts were
incubated in phosphate-buffered saline containing
0.001% Pronase E and 0.02% EDTA for 5 min at room
temperature. This incubation phase resulted in the detach-
ment of cells other than osteoclasts from the dishes, arriv-
ing at a large number of highly enriched osteoclasts [16].
Characterization of fibroblast-like cells by flow
cytometry
PLFs were trypsinized and fixed in 4% phosphate-buffered
paraformaldehyde containing 1% FCS. For extracellular
staining of human PLFs, the fibroblast surface specific
antibody (clone AS02; Dianova, Hamburg, Germany) was
used together with an anti-CD68 antibody (clone KP1;
Signet laboratories Inc, Dedham, MA, USA). Cells were
incubated with the primary antibodies for 30 min and a
FITC-labeled goat anti-mouse IgG for 20 min. The analysis
was performed on a FACS Calibur (Becton Dickinson,
Heidelberg, Germany). For intracellular fluorescent-acti-
vated cell sorter (FACS) staining of rat PLFs, cells were
treated with permeabilization buffer (0.1% saponine in
phosphate-buffered saline, 0.1M hepes and 1% FCS) and
stained with anti-prolyl-4-hydroxylase (clone 6-9H6; DPCR165
Biermann, Bad Nauheim, Germany) and anti-CD68 (clone
ED1; DPC Biermann), accordingly. All incubation and
washing steps were performed in permeabilization buffer.
SCID mouse coimplantation experiments
Two-week-old, female SCID mice were provided by the
Charles River GmbH (Sulzfeld, Germany). Normal human
articular bone was obtained from the femoral head of a
patient undergoing joint replacement surgery for severe
trauma. The implantation of PLFs from three patients,
together with bone, was performed as described for RA
synovial fibroblasts [17]. After 60 days, mice were sacri-
ficed and the implants removed. Tissue preparation
included fixation in 4% buffered formalin and paraffin
embedding according to standard procedures. Sections
(4µm) sections were stained with haematoxylin and eosin
prior to examination.
Identification of human fibroblasts in the SCID mouse
Human fibroblasts were identified in the mouse sections
with monoclonal mouse anti-vimentin antibodies (clone
V9; Dako, Hamburg, Germany) using the Vector Mouse on
Mouse immunodetection kit (Vector Laboratories Inc.,
Burlingame, CA, USA). Colour development was per-
formed with 3,3′-diaminobenzidine, and sections were
counterstained with methyl green. For negative control,
mouse IgG was used instead of the primary antibodies.
Release of acidic components
The release of acidic components by human PLFs was
measured using a cytosensor microphysiometer (Molecu-
lar Devices Corporation, Sunnyvale, CA, USA), as
described previously [18]. Cells were activated by the
cyclic influx of medium containing human recombinant
tumour necrosis factor (TNF)-α (at a concentration
between 1 and 300ng/ml; Roche Biochemicals, Basel,
Switzerland), ionomycin (10µg/ml; Biomol, Hamburg,
Germany) or control medium. For the ionomycin measure-
ments, dimethylsulfoxide was included in the control
medium. After 90s, influx was stopped and acidification
was determined over a period of 30s [18,19].
Induction–response cycles were recorded for 45 min. To
analyze the effects of ATPase inhibitors on the release of
H+, cells were treated by cyclic influx of medium contain-
ing amiloride (Calbiochem, Bad Soden, Germany) at con-
centrations between 100µmol/l and 1mmol/l, bafilomycin
A1 (Calbiochem) at concentrations between 10–8mol/l
and 10–5mol/l, or control medium.
ICSS Wistar rat model of aseptic prosthesis loosening
Male Wistar rats (age 18–22 weeks, weight 350–400g)
were obtained from Harlan Winkelmann GmbH (Borchen,
Germany). Implantation of the electrodes and the hemi-
arthroplasties were performed under general anaesthesia,
as previously described [14]. Briefly, bipolar electrodes
were implanted into the medial forebrain bundle of the
animals using a stereostactic device. For running exercise,
the electrodes were connected to the running wheel
(diameter 25cm; width 8cm) through an electronic
switch. While running in the wheel, the rats received
switch-triggered stimuli of 100ms duration (current
0.3–1.0mA). This electrical stimulation causes positive
reinforcement in the rats and results in a running load that
exceeds normal running activity by up to 100-fold [20]. For
the implantation of prostheses, an arthrotomy of the left
knee was performed through medial parapatellar incision.
The anterior cruciate ligaments and the menisci were
excised, whereas the posterior cruciate ligaments were
preserved. The articular cartilage and the most superficial
bone were resected from the tibial condyles and a hole
was drilled into the tibial plateau. The prostheses were
then inserted together with cement and compressed
axially. Prostheses were examined by radiography. After
implantation of the prostheses, rats were given 1 week to
recover from surgery before the running exercise was initi-
ated, as described above [20]. After 12 weeks, the knee
joints containing the hemi-arthroplasties were harvested
and used for isolation of fibroblast-like cells as well as his-
tological examination following embedding in paraffin.
Dentin pit resorption assay
The dentine resorption assay was performed as described
previously [21]. Dentin slices (300–400µm thick; kindly
provided by R Willmann, Institute of Zoology and Anthro-
pology, University of Göttingen, Göttingen, Germany)
were cut using a low-speed, diamond saw and cleaned by
sonication in distilled water for 30 min. Fibroblasts from
two APL patients or osteoclasts were seeded on the
dentine slices and cultured in Dulbecco’s modified Eagle’s
medium with 10% FCS and 2% penicillin/streptomycin,
with and without TNF-α (10ng/ml and 100ng/ml). Dentin
slices were fixed in 2.25% glutaraldehyde in 0.1mol/l
cacodylate buffer for 4 hours. They were then dehydrated
in ethanol, dried in a critical point dryer, mounted on stubs,
and Au:Pl coated in a cold spatter coater. The samples
were examined by scanning electron microscopy (DSM
960; Zeiss, Jena, Germany).
Results
Human prosthesis loosening fibroblasts produce signs
of bone resorption in the SCID mouse coimplantation
model
To investigate the potential of human PLFs to resorb bone
in vivo, fourth passage PLFs were coimplanted together
with normal human bone into SCID mice. When investi-
gated 60 days after implantation, PLFs were found to be
attached to the bone surface (Fig. 1a), and the signs of
bone resorption were most prominent at those sites at
which the inert sponge used for the implantation of PLF
had conferred close contact of the bone matrix with the
inserted cells (Fig. 1b). This behaviour was seen with all
PLFs. To demonstrate the human origin of the fibroblast-
Available online http://arthritis-research.com/content/5/3/R163like cells that were found at sites of bone resorption in the
SCID mice, we performed immunohistochemistry with
monoclonal antibodies against the intermediate filament
protein vimentin. These antibodies stain human cells of
mesenchymal origin but specifically do not detect vimentin
in mouse cells [22]. Immunohistochemistry showed the
presence of vimentin-positive human PLFs in all samples,
with most prominent staining at sites of bone resorption
(Fig. 1c). Adjacent mouse tissue did not stain with the
antibodies, and we observed no staining in isotype control
experiments. To investigate potential effects of osteo-
clasts, serial sections of all implants were screened for the
presence of murine multinucleated, osteoclast-like cells.
Interestingly, no such cells were seen at sites of bone
resorption in any sample.
Characterization of human prosthesis loosening
fibroblasts
In order to exclude the contamination of PLF with cells of
the monocyte/macrophage lineage, fourth passage PLFs
were characterized by flow cytometry. FACS staining for
the macrophage lineage marker CD68 was negative in all
cultures (<0.1%; Fig.2a). Moreover, the common leuco-
cyte marker CD45 was also absent all cultures (<0.1%;
Fig.2b). In contrast, all of the PLFs (>99%) stained posi-
tive for the fibroblast markers D7-Fib (Fig.2c) and AS02
(Fig.2d), confirming their identity as fibroblasts.
Resorption of dentin by human prosthesis loosening
fibroblasts in vitro
Next, we investigated the ability of human PLFs to form
resorption pits on whale dentin slices in vitro. PLFs were
cultured on dentin slices for up to 4 weeks. Following
removal of the cells, the formation of resorption pits was
assessed by scanning electron microscopy. Pit formation
by PLFs was compared with that by osteoclasts differenti-
ated freshly in vitro. After 4 weeks on dentin slices, all
PLFs exhibited morphological signs of bone resorption
and produced characteristic resorption pits (Fig.3a). Addi-
tion of 10ng/ml TNF-α (Fig.3b) and 100ng/ml TNF-α
(Fig.3c) enhanced the resorption of dentin by PLFs.
Dentin slices on which no PLFs were cultured had a clear
and smooth surface (Fig.3d) and no superficial erosions
were seen, thus excluding the possibility that the PLF-gen-
erated resorption pits were artifacts. As expected, osteo-
clasts produced characteristic resorption pits after
4–14 days (Fig.3e) but there were considerable differ-
ences between different osteoclast cultures (Fig.3f).
Resorption of dentin by early differentiation prosthesis
loosening fibroblasts from the ICSS Wistar rat model
In a further step, we sought to resolve the issue of whether
bone resorption by fibroblast-like cells can be observed in
fibroblasts from very early stages of SLIM formation. We
implanted cemented tibial hemi-arthroplasties into the left
knees of adult male Wistar rats and exposed the animals
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Figure 1
Fibroblast-like cells from the synovial-like interface membrane around
loose joint arthroplasties produce signs of bone resorption in the
severe combined immunodeficient (SCID) mouse model of matrix
degradation. (a) and (b) Cultured prosthesis loosening fibroblasts
(PLFs) were soaked into a collagen sponge and coimplanted with
normal human bone under the renal capsule of SCID mice. After
60 days, histological evaluation showed attachment and invasion of the
PLFs into the bone matrix (a, magnification ×630). The presence of
PLFs in resorption pits was seen predominantly at sites at which the
cells left the collagen sponge (b, magnification ×630). (c)
Immunohistochemistry with antivimentin antibodies that recognize
human fibroblasts but not mouse cells demonstrated the human origin
of the fibroblast-like cells invading the bone. Human, vimentin-positive
PLFs (arrowheads) were found abundantly in the SCID mouse
sections (c, magnification ×630) and exhibited close contact to the
resorption lacunae.to excessive running in a running wheel by ICSS. As
demonstrated previously [14], through positive reinforce-
ment, ICSS results in running exercise that exceeds
normal running activity of Wistar rats by up to 100-fold
and leads to the development of a SLIM. This tissue
shows all characteristics of the human SLIM but reflects
very early stages of membrane formation. In the present
study, we observed radiological signs of prosthesis loos-
ening in the ICSS rats after 12 weeks (Fig.4a). At this
time point, we removed the periprosthetic SLIM, and histo-
logical examination revealed the presence of fibrous tissue
with numerous fibroblast-like cells at sites of bone resorp-
tion (Fig.4b), which corresponds to our previous observa-
tions. We used one part of the tissue to establish rat PLFs
that were cultured over four passages. As done with the
human PLFs, we excluded contamination of PLFs with
cells of the monocyte/macrophage lineage by flow cytom-
etry. There was no FACS staining with antibodies against
CD68 (Fig.4c) and more than 99% of rat PLFs stained
positive with specific antibodies against prolyl-4-hydroxy-
lase (Fig.4d). Culturing the rat PLF on whale dentine
slices for 4 weeks produced clear resorption pits
(Fig.4e,f).
Prosthesis loosening fibroblasts release acidic
components upon stimulation
Because decalcification of the osseous matrix is a prereq-
uisite for bone resorption, we investigated further the
capability of the aggressive PLFs to release acidic compo-
nents. We used ultrasensitive pH measurement in the
direct pericellular environment with a cytosensor micro-
physiometer. Stimulation of PLFs with a calcium-depen-
dent signal, as induced by the addition of ionomycin,
resulted in rapid and significant release of acidic compo-
nents. This was seen from an increase in the rate of acidifi-
cation (maximum acidification rmax per cycle adjusted to
the equilibrium value req) by 5% after 20 min (data not
shown). Stimulation of PLFs with TNF-α at different con-
centrations had even stronger effects. Although incubation
of PLF with 1ng/ml human recombinant TNF-α did not
result in a significant stimulation of PLFs, adding 10, 100
and 300ng/ml TNF-α resulted in substantial acidification
of the pericellular milieu (Fig.5a). Consistent with our data
on TNF-α-mediated increase in the resoprtion of dentin,
we detected maximal pericellular acidification (rmax/req) of
15% with 10ng/ml TNF-α after 20 min (Fig.5b).
To test potential mechanisms through which PLFs release
acidic components, we studied the effects of ATPase
inhibitors on the pericellular acidification. Specifically, we
used the ATPase inhibitor amiloride at high concentrations
to inhibit vacuolar type (v-)ATPases [23], as well as the
specific v-ATPase inhibitor bafilomycin A1 [24], at different
concentrations to analyze the time course of H+ release as
compared with that from untreated PLFs. Addition of
amiloride at concentrations between 50µmol/l and
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Figure 2
Characterization of cultured human prosthesis loosening fibroblasts
(PLFs) by flow cytometry. (a) When compared with isotype control
staining, analysis for the macrophage lineage marker CD68 showed no
surface expression (<0.1%). (b) Also, no expression of the leucocyte
common antigen CD45 was found on the cells (<0.1%). (c) However,
fluorescent-activated cell sorter analysis with the fibroblast marker
D7-Fib revealed the fibroblast nature of the cells (>99%). (d) In
addition, more than 99% of the PLFs stained positive for the fibroblast
marker AS02.1mmol/l decreased the pericellular acidification by 32%,
as seen from a significant increase in pericellular pH
(Fig.5c). Interestingly, this inhibition of H+ release was
already evident after 3 min and remained stable for the total
measuring time of 45 min without further increase. Pericel-
lular pH returned to the initial values shortly after amiloride
perfusion was stopped (Fig.5d). Addition of the specific
v-ATPase inhibitor bafilomycin A1 resulted in up to 11%
inhibition of pericellular acidification at concentrations of
10–6mol/l (Fig.5c). Again, the effect was seen at 5 min
after addition of bafilomycin A1, but in contrast to amiloride
the secretion of protons was blocked irreversibly (Fig.5e).
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Figure 3
Human prosthesis loosening fibroblasts (PLFs) form resorption pits on whale dentin slices in vitro. (a) After 4 weeks of culture on dentin slices,
PLFs exhibited morphological signs of bone resorption and produced characteristic signs of resorption pits (closed arrowheads) with remains of
PLFs still in situ (open arrowheads). (b) Addition of 10ng/ml tumour necrosis factor (TNF)-α to the medium enhanced the resorption of dentin, as
seen from multiple resorption pits (closed arrowheads). Again, remains of PLFs were seen on the dentin slices (open arrowheads). (c) TNF-α
100ng/ml also enhanced the size of the resorption pits generated by the PLFs (closed arrowhead). (d) Dentin slices on which no PLFs were
cultured showed a clear and smooth surface and no erosions were seen. (e) Freshly differentiated osteoclasts that were used as controls
produced characteristic resorption pits after 4 days (closed arrowhead). (f) However, there were considerable differences between osteoclast
cultures, with some osteoclasts starting bone resorption only after 2 weeks (closed arrowhead).Discussion
A growing body of evidence suggests a critical involvement
of fibroblast-like cells in the destruction of extracellular
matrix in various pathologies. Both APL and RA are charac-
terized by aggressive growth and fibrotic remodelling.
However, the mechanisms that result in the occurrence of
aggressive fibroblast-like cells remain unclear. Specifically,
it is not known in detail how environmental factors translate
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Figure 4
Resorption of whale dentin by early differentiation prosthesis loosening fibroblasts (PLFs) from the intracranially self-stimulated (ICSS) Wistar rat
model of aseptic prosthesis loosening. (a) Cemented tibial hemi-arthroplasties that were implanted into the left knees of ICSS Wistar rats exhibited
radiological signs of loosening (arrows) after 12 weeks of stimulated running in a running wheel. (b) Histological evaluation of the interface tissue
between the prosthesis and the bone revealed the presence of loose fibrous tissue with fibroblast-like cells, particularly at sites of bone resorption.
(c) and (d) Characterization of rat PLFs that were established from this tissue demonstrated the identity of these cells as fibroblasts in that more
than 99% of the cells stained positive with specific antibodies against prolyl-4-hydroxylase (d), whereas there was no staining with antibodies
against the monocyte lineage marker CD68 (c). (e) and (f) Culturing the rat PLFs on sperm whale dentine slices for 4 weeks produced clear
resorption pits (closed arrowheads). Remains of the PLFs were seen in close contact with the resorption pits (open arrowheads).into the peculiar feautures that are exhibited by activated
fibroblasts in different disorders. Based on the observation
that in RA the aggressive phenotype of fibroblasts is main-
tained in the absence of inflammatory stimuli [17], it has
been hypothesized that activated fibroblasts are perma-
nently imprinted or altered by the specific environment
[25]. However, the question of how this imprinting is main-
tained in the cells remains to be answered.
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Figure 5
Release of acidic components by prosthesis loosening fibroblasts (PLFs). (a) and (b) Cytosensor measurement of PLFs stimulated with tumour
necrosis factor (TNF)-α (1, 10 and 300ng/ml) revealed the release of acidic components, with maximal pericellular acidification (rmax/req) of 15% at
10ng/ml TNF-α (A). Recording of the time curve with 10ng/ml TNF-α showed a maximal acidification 15 min after the influx of TNF-α was started
(b). (c) Incubation of PLFs with the ATPase inhibitors amiloride and bafilomycin A1 at different concentrations decreased the pericellular
acidification by a maximum of 32% with amiloride and 11% with bafilomycin A1. (d) Inhibition of H+ release by amiloride was recorded after 3 min
and remained stable for the total measuring time of 45 min. Pericellular pH returned to the initial values shortly after the perfusion of amiloride was
terminated. (e) The specific v-ATPase inhibitor bafilomycin A1 at concentrations of 10–6mol/l showed a clear effect shortly after its addition, and
the H+ secretion remained low even after discontinuation of bafilomycin A1 infusion.In this context, APL is of special interest because it allows
one to study directly the development of an aggressive
synovial-like membrane from the bone marrow. To test the
invasive behavior of PLFs, we used the well established
SCID mouse model of matrix destruction [1,26]. In this
model, fibroblast-like cells are implanted with normal
human cartilage or bone into SCID mice. Because of their
lack of a functional immune system, the mice do not reject
the implants, and this allows study of the invasive behav-
iour of the fibroblasts in the absence of other human cells.
The invasion of PLFs into cartilage in the SCID mouse
model indicates that activated fibroblast-like cells, compa-
rable to those in RA, can also be found in APL. At the
same time, this observation raises the question as to
whether differentiation of activated PLFs at the bone
surface results in the ability of the cells to resorb osseous
matrix, which is the target tissue in APL.
In the present study, we showed that fibroblasts that
develop at the interface of bone and prosthesis in APL
produce signs of bone resorption even in the absence of
osteoclasts. Following coimplantation with femoral bone
into SCID mice, resorption lacunae were found at sites of
close contact between PLFs and the bone. The conclu-
sion that osteoclasts may not be required for this process
is derived from our experimental approach in the SCID
mouse studies, in which we excluded the presence of
human macrophages and osteoclasts in the implants.
Immunohistological analysis clearly demonstrated the
human nature of cells invading the coimplanted bone, and
no murine osteoclasts were observed at sites of bone
resorption in the SCID mice. However, we cannot com-
pletely exclude the possibility that murine osteoclasts that
may be stimulated by the PLFs were present and con-
tributed to our findings, and it may be argued that the
complexity of this in vivo system makes it difficult to inves-
tigate all potential cellular interactions that may influence
bone resorption. Therefore, it is of importance that isolated
PLF produced clear resorption pits when cultured on
dentin for 4 weeks and that dentin pit formation was
enhanced visibly by addition of TNF-α. As compared with
osteoclasts, PLF-generated resorption pits were similar to
the early phases of osteoclastic bone resorption.
Of note, human PLFs in the present study were derived
from late stage APL. Such tissue is rather fibrous [2] and,
similar to the hyperplastic synovial membrane in RA, con-
tains different subpopulations of fibroblast-like cells.
Therefore, we investigated whether an ability of PLFs to
resorb bone can also be identified in fibroblast-like cells
from very early stages of SLIM formation. We used the
ICSS Wistar rat model of APL [14] and demonstrated that
the first signs of APL are found after 12 weeks. PLFs from
the loose fibrous tissue that constitutes the SLIM at this
early phase were capable of bone resorption, as shown on
dentin slices. The morphology of these resorption pits was
close to that seen in early osteoclasts, but the experimen-
tal approach and flow cytometry excluded contamination
of the PLF cultures with cells of the monocyte/
macrophage lineage. These findings complement our data
from human cells by showing that PLFs acquire the ability
to resorb bone early in their differentiation. Because the
development of SLIM tissue cannot be studied in humans,
our data demonstrate also value of the ICSS Wistar rat
model for investigating early events in SLIM formation
[14]. Moreover, this model provides a unique opportunity
to study the characteristic features of fibroblasts during
their development into aggressive matrix-degrading cells
under standardized conditions.
Because it is known that fibroblasts both in RA and APL
express enzymes, including membrane-type 1 matrix met-
alloproteinases and cathepsin K, which have been impli-
cated in bone resorption [7,27], a major question related
to the ability of fibroblasts to resorb bone is that of how
these cells decalcify the osseous matrix before its degra-
dation. Here, we show that, upon stimulation, PLFs
release acidic components that result in a significant drop
in the pericellular pH. This may be achieved by artificial
calcium-dependent signaling with ionomycin and with
TNF-α, that has been shown to be expressed abundantly
within the SLIM [28]. Certainly, the drop in pH upon stimu-
lation reflects metabolic activation of the PLFs, but it may
also provide a mechanism by which these cells contribute
to the decalcification of the bone matrix. Although the data
presented here do not clarify specific mechanisms by
which PLFs produce the acidic components, the expres-
sion of a specific H+-ATPase on their cell membrane may
potentially provide an explanation. It has been suggested
that ATPases contribute to the H+ secretion not only by
osteoclasts [29] but also by other cells, including tubular
kidney cells and cells of the inner ear [30]. It may therefore
be hypothesized that similar mechanisms operate in PLFs.
This notion is supported by the demonstration that spe-
cific inhibition of ATPases decreased pericellular acidifica-
tion. Particularly, the use of bafilomycin A1 – a specific
inhibitor of v-ATPases – resulted in an irreversible inhibi-
tion of pericellular acidification. The observation that the
release of H+ is inhibited even after 5 min argues in favour
of rapid membrane-associated mechanisms rather than
slow transport of acidic equivalents from inside the cells.
It must be emphasized that osteoclasts constitute the
major cell type involved in the degradation of bone not
only under physiological conditions but also in disease. In
the present study this is reflected clearly both by the
extent and time course of osteoclast-mediated resorption
of dentin. Notably, the most aggressive osteoclast cultures
produced resorption pits even after 4 days, and those that
showed less activity exhibited the first signs of dentin
resorption after 14 days. In contrast, dentin resorption by
PLFs was seen only after 4 weeks. In this regard, our data
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like cells differentiating under specific conditions such as
APL may contribute directly to bone resorption. The data
therefore contribute to the controversial discussion of
whether degradation of calcified bone is linked exclusively
to osteoclasts. Although studies by Chambers and Horton
[31] failed to demonstrate bone resorption by mononu-
clear phagocytes, other observations suggested that
tumour-infiltrating macrophages [32], as well as poly-
methylmethacrylate-induced inflammatory macrophages
[33], are capable of bone resorption in a specific interac-
tion with stromal cells. In this context, the present results
shed new light both on non-osteoclast-mediated bone
resorption and on the role of fibroblast-like cells therein.
The generation of an acidic milieu and the expression of
bone-degrading enzymes may provide the tools for acti-
vated PLFs to degrade actively the osseous matrix in APL.
This notion not only stresses the role of activated fibrob-
last-like cells in this process but may also provide novel
targets to inhibit bone resorption.
Conclusion
Although the possibility that mesenchymal cells may
resorb bone has been rejected by some investigators, we
demonstrate here for the first time that fibroblasts not only
enhance but also actively contribute to bone resorption. In
prosthesis loosening, PLFs appear to acquire this feature
early in their differentiation. It is concluded that fibroblasts
should be considered a target for preventing bone resorp-
tion in prosthesis loosening and potentially other condi-
tions of bone loss.
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